An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod.

ABSTRACT:

Objectives

To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc).

Methods

In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod for 8 weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up for the analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the number of myofibroblasts. The safety of paquinimod was evaluated throughout the study.

Results

Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3 mg/day for 8 weeks. After the treatment, a reduction of type I IFN activity in the plasma from one

SUBMITTER: Hesselstrand R 

PROVIDER: S-EPMC8325221 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature